BETA: Please send your feedback!
Neurotrope
NTRP:NAS
Medical Specialties
—
MICRO cap
(—)
—
since start of 2021
—
About
Medical Specialties
Founded 2013
Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. It operates through the following geographical segments: US; European Union; Japan; and China and India. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on June 13, 2013 and is headquartered in New York, NY.
website
Headquarters
Executives
| Name | Title | Gender |
| Robert Weinstein, MBA, CPA | Chief Financial Officer, Secretary & Treasurer | Male |
| Susanne Wilke, PhD, MBA | Chief Executive Officer & Director | Female |
| Joshua N. Silverman | Chairman | Male |
| Daniel Alkon, MD | President & Chief Scientific Officer | Male |
Mindful Investing Summary
Neurotrope - Competitors and Related Companies
How Neurotrope stacks up to its peers in the Medical Specialties industry or with competing business segments.
Neurotrope
NTRP:NAS
Medical Specialties
—
MICRO cap
(—)
—
since start of 2021
—
Loading…